Home » THERAVANCE INITIATES PHASE I STUDY WITH INVESTIGATIONAL MEDICINE FOR GASTROINTESTINAL MOTILITY DYSFUNCTION
THERAVANCE INITIATES PHASE I STUDY WITH INVESTIGATIONAL MEDICINE FOR GASTROINTESTINAL MOTILITY DYSFUNCTION
Theravance has enrolled the first subjects in a Phase I clinical study designed to assess the safety, tolerability and pharmacokinetics of its investigational gastrointestinal (GI) prokinetic, TD-2749.
TD-2749 is a selective 5-HT4 agonist discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct